Last updated on April 19, 2014 at 5:20 EDT

Latest Scioderm Stories

2013-04-26 08:23:58

Proceeds to fund clinical development through registration for use of SD-101 for the treatment of patients with Epidermolysis Bullosa (EB) DURHAM, N.C., April 26, 2012 /PRNewswire-iReach/ -- Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling $16 million. Morgenthaler Ventures led the Series A financing, with Technology Partners as the second investor participating in the round. (Photo:...

2013-02-13 20:21:47

RALEIGH, N.C., Feb. 13, 2013 /PRNewswire-iReach/ -- Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for SD-101 to proceed. SD-101 is a topical treatment being developed for the treatment of Epidermolysis Bullosa (EB). The Company plans to initiate a Phase 1 study in the coming months, with initiation of the Phase 2B/3 study in EB patients to occur in the second half of 2013. EB is a rare genetic...